TCW Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

TCW Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-11,904	Closed	-$837K	–	569
2016 Q4	$837K	Sell	11,904 -135	-1%	-$9.58K	0.01%	529
2016 Q3	$854K	Sell	12,039 -4,414	-27%	-$282K	0.01%	514
2016 Q2	$804K	Buy	16,453 +3,989	+32%	+$258K	0.01%	529
2016 Q1	$789K	Sell	12,464 -2,595	-17%	-$170K	0.01%	542
2015 Q4	$1.69M	Sell	15,059 -61	-0.4%	-$6.1K	0.01%	392
2015 Q3	$1.46M	Sell	15,120 -8,114	-35%	-$929K	0.01%	427
2015 Q2	$2.38M	Sell	23,234 -8,152	-26%	-$633K	0.02%	356
2015 Q1	$1.95M	Sell	31,386 -6,287	-17%	-$349K	0.01%	631
2014 Q4	$1.65M	Sell	37,673 -10,009	-21%	-$459K	0.01%	643
2014 Q3	$2.7M	Sell	47,682 -4,225	-8%	-$213K	0.01%	622
2014 Q2	$2.33M	Buy	51,907 +27,720	+115%	+$1.14M	0.01%	650
2014 Q1	$1.18M	Buy	+24,187	New	+$1.25M	﹤0.01%	704

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

CGT

Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

TCW Group's RARE Position: Q1 2017 in Review

TCW Group sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2017, closing a stake of 11,904 shares — an estimated $837K sold.

TCW Group first reported a position in RARE in Q1 2014 and held it in 12 quarters. The position peaked at $2.7M in Q3 2014. 164 funds tracked by Wall St. Rank hold RARE as of Q1 2017.

TCW Group reported no remaining Ultragenyx Pharmaceutical position as of Q1 2017 after selling out during the quarter.
TCW Group sold 11,904 Ultragenyx Pharmaceutical shares in Q1 2017, an estimated $837K.
TCW Group first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 12 quarters.
TCW Group's Ultragenyx Pharmaceutical position peaked at $2.7M in Q3 2014.
164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2017.

Based on TCW Group's 13F filing for Q1 2017, filed 12 May 2017.